Medartis Holding AG
SIX:MED
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
52
89.4
|
Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one MED stock under the Base Case scenario is 87.83 CHF. Compared to the current market price of 52 CHF, Medartis Holding AG is Undervalued by 41%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Medartis Holding AG
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for MED cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Medartis Holding AG
Balance Sheet Decomposition
Medartis Holding AG
Current Assets | 258.1m |
Cash & Short-Term Investments | 127.1m |
Receivables | 50m |
Other Current Assets | 81m |
Non-Current Assets | 206.4m |
Long-Term Investments | 35.2m |
PP&E | 79.7m |
Intangibles | 60.1m |
Other Non-Current Assets | 31.3m |
Current Liabilities | 57.1m |
Accounts Payable | 7.5m |
Accrued Liabilities | 6.5m |
Other Current Liabilities | 43.1m |
Non-Current Liabilities | 134.8m |
Long-Term Debt | 114.7m |
Other Non-Current Liabilities | 20.1m |
Earnings Waterfall
Medartis Holding AG
Revenue
|
220.3m
CHF
|
Cost of Revenue
|
-42.9m
CHF
|
Gross Profit
|
177.4m
CHF
|
Operating Expenses
|
-167.8m
CHF
|
Operating Income
|
9.6m
CHF
|
Other Expenses
|
-5.6m
CHF
|
Net Income
|
4m
CHF
|
Free Cash Flow Analysis
Medartis Holding AG
CHF | |
Free Cash Flow | CHF |
In the first half of the year, a series of mix effects triggered a gross margin decline by approximately 250 basis points. These effects included manufacturing sales dilution, distributor sales depressions, and inventory efficiency initiatives reducing production utilization. Nevertheless, the company sees these impacts diminishing in the second half. Operating expenses (OpEx) decreased around 7 percentage points year-on-year, indicating strong business leverage and confidence in meeting the full-year EBITDA margin guidance. Despite a CHF 50 million cash outflow and increased investments, the management expects H2 cash outflow to be significantly lower due to working capital improvements, non-recurrence of certain investments, and anticipated higher sales and gross margins. Consolidating the U.S. office to Warsaw improved the cost basis, with potential for expanding in various medical indications. The company confirms guidance for the full year, with internal sales growth between 15-18% and an EBITDA margin of 13-15%.
What is Earnings Call?
MED Profitability Score
Profitability Due Diligence
Medartis Holding AG's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
Score
Medartis Holding AG's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
MED Solvency Score
Solvency Due Diligence
Medartis Holding AG's solvency score is 74/100. The higher the solvency score, the more solvent the company is.
Score
Medartis Holding AG's solvency score is 74/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MED Price Targets Summary
Medartis Holding AG
According to Wall Street analysts, the average 1-year price target for MED is 104.52 CHF with a low forecast of 93.32 CHF and a high forecast of 115.5 CHF.
Dividends
Current shareholder yield for MED is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Medartis Holding AG operates as a medical device company. The company is headquartered in Basel, Basel-Stadt and currently employs 684 full-time employees. The company went IPO on 2018-03-23. The Group develops, manufactures and distributes to surgeons, hospitals and medical centers titanium screws, plates, surgical instruments and system solutions for internal fracture fixation. Medartis AG, the Company's wholly-owned subsidiary, has developed such technologies as TriLock for locking the screw into the plate, SpeedTip, a screw that does not require pre-drilling, and HexaDrive self-holding screw and screw-driver. The company has two product lines. The APTUS product line comprises upper and lower extremities products for hand, wrist, elbow, shoulder and foot fixation. The MODUS line combines products dedicated to cranio-maxillofacial (CMF) surgery. The Group's products are sold globally in more than 30 countries, including Germany and the United States, either directly through its sales subsidiaries, or through third-party distributors.
Contact
IPO
Employees
Officers
The intrinsic value of one MED stock under the Base Case scenario is 87.83 CHF.
Compared to the current market price of 52 CHF, Medartis Holding AG is Undervalued by 41%.